Relative inhibitory activities of the broad-spectrum β-lactamase inhibitor taniborbactam against metallo-β-lactamases

被引：12

作者：

Le Terrier, Christophe ^{[1
,2
]}

Viguier, Clement ^{[1
,3
]}

Nordmann, Patrice ^{[1
,4
]}

Vila, Alejandro J. ^{[5
,6
,7
]}

Poirel, Laurent ^{[1
,4
]}

机构：

[1] Univ Fribourg, Fac Sci & Med, Emerging Antibiot Resistance Med & Mol Microbiol, Fribourg, Switzerland

[2] Univ Hosp Geneva, Div Intens Care Unit, Geneva, Switzerland

[3] Univ Hosp Toulouse, Infect Dis Dept, Toulouse, France

[4] Swiss Natl Reference Ctr Emerging Antibiot Resista, Fribourg, Switzerland

[5] CONICET UNR, IBR, Inst Biol Mol & Celular Rosario, Rosario, Argentina

[6] Univ Nacl Rosario, Fac Ciencias Bioquim & Farmaceut, Area Biofis, Rosario, Argentina

[7] Cleveland VAMC Ctr Antimicrobial Resistance & Epid, CWRU, Cleveland, OH USA

来源：

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY | 2024年 / 68卷 / 02期

基金：

瑞士国家科学基金会;

关键词：

metallo-beta-lactamase; NDM; IMP; VIM; taniborbactam;

D O I：

10.1128/aac.00991-23

中图分类号：

Q93 [微生物学];

学科分类号：

071005 ; 100705 ;

摘要：

Taniborbactam (TAN) is a novel broad-spectrum beta-lactamase inhibitor with significant activity against subclass B1 metallo-beta-lactamases (MBLs). Here, we showed that TAN exhibited an overall excellent activity against B1 MBLs including most NDM- and VIM-like as well as SPM-1, GIM-1, and DIM-1 enzymes, but not against SIM-1. Noteworthy, VIM-1-like enzymes (particularly VIM-83) were less inhibited by TAN than VIM-2-like. Like NDM-9, NDM-30 (also differing from NDM-1 by a single amino acid substitution) was resistant to TAN.

引用

页数：8

共 20 条

[1] Metallo-β-lactamases in the Age of Multidrug Resistance: From Structure and Mechanism to Evolution, Dissemination, and Inhibitor Design
Bahr, Guillermo
Gonzalez, Lisandro J.
Vila, Alejandro J.
[J]. CHEMICAL REVIEWS, 2021, 121 (13) : 7957 - 8094
[2] The Emergence of Carbapenem Resistant Enterobacteriaceae Producing GIM-1 and SIM-1 Clinical Isolates in Khartoum-Sudan
Bayoumi, Magdi A.
Hamid, Omnia M.
[J]. INFECTION AND DRUG RESISTANCE, 2022, 15 : 2679 - 2684
[3] Clinical and Laboratory Standards Institute, 2023, Performance standards for antimicrobial susceptibility testing: thirty-third informational
[4] EUCAST, MIC DETERMINATION NO
[5] VNRX-5133 (Taniborbactam), a Broad-Spectrum Inhibitor of Serine- and Metallo-β-Lactamases, Restores Activity of Cefepime in Enterobacterales and Pseudomonas aeruginosa
Hamrick, Jodie C.
Docquier, Jean-Denis
Uehara, Tsuyoshi
Myers, Cullen L.
Six, David A.
Chatwin, Cassandra L.
John, Kaitlyn J.
Vernacchio, Salvador F.
Cusick, Susan M.
Trout, Robert E. L.
Pozzi, Cecilia
De Luca, Filomena
Benvenuti, Manuela
Mangani, Stefano
Liu, Bin
Jackson, Randy W.
Moeck, Greg
Xerri, Luigi
Burns, Christopher J.
Pevear, Daniel C.
Daigle, Denis M.
[J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2020, 64 (03)
[6] Bicyclic Boronate VNRX-5133 Inhibits Metallo- and Serine-β-Lactamases
Krajnc, Alen
Brem, Jurgen
Hinchliffe, Philip
Calvopina, Karma
Panduwawala, Tharindi D.
Lang, Pauline A.
Kamps, Jos J. A. G.
Tyrrell, Jonathan M.
Widlake, Emma
Saward, Benjamin G.
Walsh, Timothy R.
Spencer, James
Schofield, Christopher J.
[J]. JOURNAL OF MEDICINAL CHEMISTRY, 2019, 62 (18) : 8544 - 8556
[7] Wide dissemination of Gram-negative bacteria producing the taniborbactam-resistant NDM-9 variant: a One Health concern
Le Terrier, Christophe
Nordmann, Patrice
Buchs, Chloe
Di, Doris Yoong Wen
Rossolini, Gian Maria
Stephan, Roger
Castanheira, Mariana
Poirel, Laurent
[J]. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2023, 78 (09) : 2382 - 2384
[8] Impact of Acquired Broad Spectrum β-Lactamases on Susceptibility to Novel Combinations Made of β-Lactams (Aztreonam, Cefepime, Meropenem, and Imipenem) and Novel β-Lactamase Inhibitors in Escherichia coli and Pseudomonas aeruginosa
Le Terrier, Christophe
Nordmann, Patrice
Freret, Charlotte
Seigneur, Marion
Poirel, Laurent
[J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2023, 67 (07)
[9] In vitro activity of cefepime/zidebactam and cefepime/taniborbactam against aztreonam/avibactam-resistant NDM-like-producing Escherichia coli clinical isolates
Le Terrier, Christophe
Nordmann, Patrice
Sadek, Mustafa
Poirel, Laurent
[J]. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2023, 78 (05) : 1191 - 1194
[10] Le Terrier C, 2023, LANCET INFECT DIS, V23, P401, DOI [10.1016/S1473-3099(23)00069-5, 10.1016/S1473-3099(23)00070-1]

← 1 2 →